Moderna, Inc. Inventory, Finished Goods, Net of Reserves
Moderna, Inc. (MRNA) had Inventory, Finished Goods, Net of Reserves of $66.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Inventory › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-07-31
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $66.00M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $14.00M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $33.00M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $128.00M.
| Period end | Inventory, Finished Goods, Net of Reserves | Inventory, Finished Goods, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $66.00M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $14.00M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $33.00M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $128.00M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $45.00M 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $14.00M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $28.00M 10-K · filed 2026-02-20 | |
| 2024-09-30 | $146.00M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $34.00M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $20.00M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $24.00M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $277.00M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $12.00M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $64.00M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $169.00M 10-K · filed 2024-02-23 | |
| 2022-09-30 | $170.00M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $142.00M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $357.00M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $233.00M 10-K · filed 2023-02-24 | |
| 2021-09-30 | $127.00M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $41.00M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $12.00M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $1.00M 10-K · filed 2022-02-25 | $1.29M 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |